

MERIDIAN PHARMA LIMITED

UNAUDITED

FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2018

FRIDAY



L7EI4LSH
LD5 14/09/2018 #67
COMPANIES HOUSE

MERIDIAN PHARMA LIMITED
REGISTERED NUMBER:06842822

BALANCE SHEET
AS AT 31 MARCH 2018

	Note	2018 £	2017 £
Fixed assets			
Intangible assets	4	69,299	87,377
Tangible assets	5	84,698	89,991
		<u>153,997</u>	<u>177,368</u>
Current assets			
Stocks	6	56,590	63,258
Debtors: amounts falling due within one year	7	85,445	90,826
Cash at bank and in hand	8	157,276	279,333
		<u>299,311</u>	<u>433,417</u>
Creditors: amounts falling due within one year	9	(85,600)	(208,854)
Net current assets		<u>213,711</u>	<u>224,563</u>
Total assets less current liabilities		<u>367,708</u>	<u>401,931</u>
Provisions for liabilities			
Deferred tax	10	(1,897)	(1,606)
		<u>(1,897)</u>	<u>(1,606)</u>
Net assets		<u>365,811</u>	<u>400,325</u>
Capital and reserves			
Called up share capital		300,000	300,000
Profit and loss account		65,811	100,325
		<u>365,811</u>	<u>400,325</u>

MERIDIAN PHARMA LIMITED
REGISTERED NUMBER:06842822

BALANCE SHEET (CONTINUED)
AS AT 31 MARCH 2018

The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the profit and loss account in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf on 4 September 2018.



D Tanna
Director

The notes on pages 3 to 10 form part of these financial statements.

MERIDIAN PHARMA LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2018

1. General information

Meridian Pharma Limited is a private limited company, registered in England and Wales with registration number 06842822. The registered office is 5th Floor, 89 New Bond Street, London, W1S 1DA and the trading address is Orchard Lodge Farm, 118 The Health, East Malling, Kent, ME19 6JL.

The principal activity of the company continues to be that of a pharmacy.

2. Accounting policies

2.1 Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Section 1A of Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006.

The following principal accounting policies have been applied:

2.2 Revenue

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

2.3 Intangible assets

Goodwill

Goodwill represents the difference between amounts paid on the cost of a business combination and the acquirer's interest in the fair value of its identifiable assets and liabilities of the acquiree at the date of acquisition. Subsequent to initial recognition, Goodwill is measured at cost less accumulated amortisation and accumulated impairment losses. Goodwill is amortised on a straight line basis to the Profit and loss account over its useful economic life.

Other intangible assets

Intangible assets are initially recognised at cost. After recognition, under the cost model, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

All intangible assets are considered to have a finite useful life. If a reliable estimate of the useful life cannot be made, the useful life shall not exceed ten years.

MERIDIAN PHARMA LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2018

2. Accounting policies (continued)

2.4 Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method and on a reducing balance basis.

Depreciation is provided on the following basis:

S/Term Leasehold Property	-	5% on a straight line basis
Motor vehicles	-	25% reducing balance basis
Fixtures and fittings	-	25% reducing balance basis

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in the Profit and loss account.

2.5 Stocks

Stocks are stated at the lower of cost and net realisable value, being the estimated selling price less costs to complete and sell. Cost is based on the cost of purchase on a weighted average basis. Work in progress and finished goods include labour and attributable overheads.

At each balance sheet date, stocks are assessed for impairment. If stock is impaired, the carrying amount is reduced to its selling price less costs to complete and sell. The impairment loss is recognised immediately in profit or loss.

2.6 Debtors

Short term debtors are measured at transaction price, less any impairment.

2.7 Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours.

2.8 Financial instruments

The Company only enters into basic financial instrument transactions that result in the recognition of financial assets and liabilities like trade and other debtors and creditors, loans from banks and other third parties, loans to related parties and investments in non-puttable ordinary shares.

2.9 Creditors

Short term creditors are measured at the transaction price. Other financial liabilities are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

MERIDIAN PHARMA LIMITED

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2018**

2. Accounting policies (continued)

2.10 Operating leases: the Company as lessee

Rentals paid under operating leases are charged to the Profit and loss account on a straight line basis over the lease term.

2.11 Pensions

Defined contribution pension plan

The Company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the Company pays fixed contributions into a separate entity. Once the contributions have been paid the Company has no further payment obligations.

The contributions are recognised as an expense in the Profit and loss account when they fall due. Amounts not paid are shown in accruals as a liability in the Balance sheet. The assets of the plan are held separately from the Company in independently administered funds.

2.12 Interest income

Interest income is recognised in the Profit and loss account using the effective interest method.

2.13 Provisions for liabilities

Provisions are made where an event has taken place that gives the Company a legal or constructive obligation that probably requires settlement by a transfer of economic benefit, and a reliable estimate can be made of the amount of the obligation.

Provisions are charged as an expense to the Profit and loss account in the year that the Company becomes aware of the obligation, and are measured at the best estimate at the Balance sheet date of the expenditure required to settle the obligation, taking into account relevant risks and uncertainties.

When payments are eventually made, they are charged to the provision carried in the Balance sheet.

MERIDIAN PHARMA LIMITED

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2018**

2. Accounting policies (continued)

2.14 Taxation

The tax expense for the year comprises current and deferred tax. Tax is recognised in the Profit and loss account, except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current corporation tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the Company operates and generates income.

Deferred tax balances are recognised in respect of all timing differences that have originated but not reversed by the Balance sheet date, except that:

- The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits; and
- Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met.

Deferred tax balances are not recognised in respect of permanent differences except in respect of business combinations, when deferred tax is recognised on the differences between the fair values of assets acquired and the future tax deductions available for them and the differences between the fair values of liabilities acquired and the amount that will be assessed for tax. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

3. Employees

The average monthly number of employees, including directors, during the year was 9 (2017 - 9).

MERIDIAN PHARMA LIMITED

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2018**

4. Intangible assets

	Goodwill £
Cost	
At 1 April 2017	180,780
At 31 March 2018	180,780
Amortisation	
At 1 April 2017	93,403
Charge for the year	18,078
At 31 March 2018	111,481
Net book value	
At 31 March 2018	69,299
At 31 March 2017	87,377

MERIDIAN PHARMA LIMITED

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2018**

5. Tangible fixed assets

	S/Term Leasehold Property £	Plant and machinery £	Motor vehicles £	Total £
Cost or valuation				
At 1 April 2017	101,684	41,716	5,546	148,946
Additions	-	3,171	-	3,171
Disposals	-	(195)	-	(195)
At 31 March 2018	<u>101,684</u>	<u>44,692</u>	<u>5,546</u>	<u>151,922</u>
Depreciation				
At 1 April 2017	23,110	31,616	4,230	58,956
Charge for the year on owned assets	4,622	3,318	329	8,269
At 31 March 2018	<u>27,732</u>	<u>34,934</u>	<u>4,559</u>	<u>67,225</u>
Net book value				
At 31 March 2018	<u>73,952</u>	<u>9,758</u>	<u>987</u>	<u>84,697</u>
At 31 March 2017	<u>78,574</u>	<u>10,101</u>	<u>1,316</u>	<u>89,991</u>

The net book value of land and buildings may be further analysed as follows:

	2018 £	2017 £
Short leasehold	73,952	78,574
	<u>73,952</u>	<u>78,574</u>

6. Stocks

	2018 £	2017 £
Finished goods and goods for resale	56,590	63,258
	<u>56,590</u>	<u>63,258</u>

MERIDIAN PHARMA LIMITED

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2018**

7. Debtors

	2018	2017
	£	£
Trade debtors	68,829	71,599
Other debtors	7,300	9,440
Prepayments and accrued income	9,316	9,787
	85,445	90,826

8. Cash and cash equivalents

	2018	2017
	£	£
Cash at bank	157,276	279,333
	157,276	279,333

9. Creditors: Amounts falling due within one year

	2018	2017
	£	£
Trade creditors	72,903	77,358
Corporation tax	-	15,749
Other creditors	6,644	110,111
Accruals and deferred income	6,053	5,636
	85,600	208,854

10. Deferred taxation

	2018	2017
	£	£
At beginning of year	(1,606)	(2,564)
Charged to profit or loss	(291)	958
At end of year	(1,897)	(1,606)

MERIDIAN PHARMA LIMITED

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2018**

10. Deferred taxation (continued)

	2018	2017
	£	£
Accelerated capital allowances	(1,982)	(1,606)
Short term timing differences	85	-
	<u>(1,897)</u>	<u>(1,606)</u>

11. Pension commitments

The company operates a defined contributions pension scheme. The assets of the scheme are held separately from those of the company in an independently administered fund. The pension cost charge represents contributions payable by the company to the fund and amounted to £965 (2017 - £Nil). Contributions totalling £496 (2017 - £Nil) were payable to the fund at the balance sheet date and are included in creditors.

12. Related party transactions

At the balance sheet date, the directors were owed £Nil (2017 - £110,000) from the company. This is an interest free loan and was settled at the balance sheet date.